2004
Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration
Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S, Group O. Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration. Journal Of The American Society Of Nephrology 2004, 16: 546-554. PMID: 15625070, DOI: 10.1681/asn.2004090793.Peer-Reviewed Original ResearchConceptsIcodextrin groupNegative net ultrafiltrationNet ultrafiltrationPeritoneal ultrafiltrationWeek 2Week 1Control groupDouble-blind trialPercentage of patientsAutomated Peritoneal DialysisPeritoneal dialysisTreatment groupsControlled EvaluationHigh transportersClinical observationsIcodextrinStudy periodBaselineLong dwellPatientsDextroseSolute removalGroupEfficiency ratioMulticenter
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors